As of Jan 22
| +0.70 / +5.17%|
The 3 analysts offering 12-month price forecasts for Stemline Therapeutics Inc have a median target of 38.00, with a high estimate of 41.00 and a low estimate of 22.00. The median estimate represents a +166.67% increase from the last price of 14.25.
The current consensus among 3 polled investment analysts is to Buy stock in Stemline Therapeutics Inc. This rating has held steady since January, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.